Clinical trial
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma: A Multicenter Randomized Clinical Phase 3 Trial
NCT04944914 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma: A Multicenter Randomized Clinical Phase 3 Trial
- Lead sponsor
- Sun Yat-sen University
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- June 1, 2021
- Completion date
- June 1, 2028
- Enrollment
- 188 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.